Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.
The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Aug 9, 24 | -0.37 Increased by +31.48% | -0.34 Decreased by -8.82% |
Jun 21, 24 | -0.18 Increased by +95.38% | -0.48 Increased by +62.50% |
Feb 12, 24 | -0.30 Decreased by -233.33% | -0.31 Increased by +3.23% |
Nov 13, 23 | -0.43 Decreased by -290.91% | -0.11 Decreased by -290.91% |
Aug 11, 23 | -0.54 Decreased by -440.00% | -0.09 Decreased by -500.00% |
Jun 23, 23 | -3.90 Decreased by -4.23 K% | -0.84 Decreased by -364.29% |
Feb 14, 23 | -0.09 Increased by +18.18% | -0.15 Increased by +40.00% |
Nov 14, 22 | -0.11 Decreased by -266.67% | - |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 24 | 0.00 Decreased by N/A% | -3.43 M Increased by +7.72% | Decreased by N/A% Decreased by N/A% |
Jun 30, 24 | 0.00 Decreased by N/A% | -2.62 M Increased by +34.95% | Decreased by N/A% Decreased by N/A% |
Mar 31, 24 | 0.00 Increased by +100.00% | -3.17 M Increased by +89.12% | Decreased by N/A% Decreased by N/A% |
Dec 31, 23 | 0.00 Decreased by N/A% | -2.39 M Increased by +38.52% | Decreased by N/A% Decreased by N/A% |
Sep 30, 23 | 0.00 Decreased by N/A% | -3.72 M Increased by +24.55% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0.00 Decreased by -100.00% | -4.02 M Increased by +11.07% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | -32.00 K Decreased by -346.15% | -29.09 M Decreased by -623.56% | Increased by +90.90 K% Increased by +393.95% |
Dec 31, 22 | 0.00 Decreased by N/A% | -3.89 M Decreased by -2.94% | Decreased by N/A% Decreased by N/A% |